Patents Examined by Eliane Lazar-Wesley
-
Patent number: 5958736Abstract: Tripartite recombinant DNA encoding fusion proteins which comprise three sequences, i.e., a signal peptide which is operable in a Gram positive bacterium, an immunogenic polypeptide linked thereto which is not normally expressed in a Gram positive bacterium, and a cell wall spanning and a membrane anchoring sequence, as well as their use in Gram positive bacteria to express the resultant fusion protein on their surface are described. The preferred cell wall spanning and anchoring polypeptides include Staphylococcus protein A and Streptococcus protein G.Type: GrantFiled: April 8, 1996Date of Patent: September 28, 1999Assignee: Pierre Fabre MedicamentInventors: Stefan St.ang.hl, Per-.ANG.ke Nygren, Marianne Hansson, Mathias Uhlen, Thien Ngoc Nguyen
-
Patent number: 5955363Abstract: Site-directed in vitro mutagenesis is obtained utilizing a specially-engineered plasmid vector. The vector is engineered to contain an inactivated genetic marker which marker is capable of being reverted to functional expression. Additionally, the vector contains a second genetic marker, a polylinker region and an f1 replication origin.Type: GrantFiled: May 17, 1993Date of Patent: September 21, 1999Assignee: Promega CorporationInventors: Martin K. Lewis, David V. Thompson
-
Patent number: 5948462Abstract: A method of preparing low fat sausage having a juicy feeling is provided by adding heat-denatured whey protein and emulsified composition comprising heat-denatured whey protein and edible oil and fat to raw material meat for sausage.The invention also provides low fat sausage which has the same meat structure and juicy feeling as usual sausage comprising animal fat such as hog fat and the like.Type: GrantFiled: March 25, 1997Date of Patent: September 7, 1999Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Eiji Atsuta, Maki Maeda, Kaoru Sato, Masami Kawanari
-
Patent number: 5948890Abstract: Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed were methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein coupled receptor polypeptides. Also disclosed are diagnostic methods for detecting a mutation in the G-protein coupled receptor nucleic acid sequences and an altered level of the soluble form of the receptors.Type: GrantFiled: April 1, 1998Date of Patent: September 7, 1999Assignee: Human Genome Sciences, Inc.Inventors: Daniel R. Soppet, Yi Li, Craig A. Rosen, Steven M. Ruben
-
Patent number: 5945301Abstract: The invention relates to a kinase which is activated by transforming growth factor-.beta. (TGF-.beta.) and funstions in the TGF-.beta. family signal tranduction system. The invention further relates to a process of producing said kinase and to a gene encoding said kinase.Type: GrantFiled: July 24, 1996Date of Patent: August 31, 1999Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Naoto Ueno, Kunihiro Matsumoto, Kenji Irie
-
Patent number: 5936064Abstract: An acid-labile protein is described that, when incubated with the 53-Kd acid-stable protein occupied by IGF, converts it to a high molecular weight complex, corresponding to the in vivo form of IGF. This protein is called the acid-labile subunit (ALS) of IGF binding protein complex and is provided in biologically pure form. ALS is useful in treating wounds and promoting cellular growth. The nucleic acid encoding ALS, antibodies binding thereto, and fragments thereof are also disclosed.Type: GrantFiled: June 2, 1995Date of Patent: August 10, 1999Assignee: Central Sydney Area Health ServiceInventor: Robert Charles Baxter
-
Patent number: 5925548Abstract: Engineered cell surface receptors are described that are constitutively active in the absence of the cytokine, hormone or molecule that normally activates the receptor. Receptors that constitutively signal are generally created by engineering the receptor to form multimers at the cell surface. Disclosed are various DNA, protein and cellular compositions and methods of making and using such constitutively active receptors. Particular examples are fusion proteins in which the stem, transmembrane domain and cytoplasmic domain are derived from a TNF receptor, and the extracellular, multimerizing domain is derived from an erythropoietin receptor. Transfection of such fusion protein constructs into cells is shown to result in a strong cytotoxic effect.Type: GrantFiled: December 9, 1996Date of Patent: July 20, 1999Assignee: Board of Regents, The University of Texas SystemInventors: Bruce A. Beutler, Flavia M. Bazzoni
-
Patent number: 5916758Abstract: Isolated nucleic acid encoding human smooth muscle cell-derived migration factor, protein obtainable from the nucleic acid, recombinant host cells transformed with the nucleic acid and use of the protein and nucleic acid sequence are disclosed.Type: GrantFiled: April 23, 1997Date of Patent: June 29, 1999Inventors: Mark Robert Hurle, Peter Colon McDonnell, Dean Edward McNulty, Craig Alan Rosen, Ivo Rogulia Siemens, Peter Ronald Young, Tian-Li Yue
-
Patent number: 5891674Abstract: The invention provides a human insulin receptor tyrosine kinase substrate (IRS-p53h) and polynucleotides which identify and encode IRS-p53h. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IRS-p53h.Type: GrantFiled: June 19, 1997Date of Patent: April 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Purvi Shah
-
Patent number: 5891673Abstract: Murine Lck binding protein ("LckBP1"), cDNA encoding for LckBP1, and protein and cDNA fragments and analogs, are cloned and expressed and characterized.Type: GrantFiled: October 1, 1997Date of Patent: April 6, 1999Assignee: Syntex (U.S.A.) Inc.Inventors: Yasuhiro Hashimoto, Yoshihiro Takemoto
-
Patent number: 5885579Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.Type: GrantFiled: July 8, 1997Date of Patent: March 23, 1999Assignee: Briston-Myers Squibb CompanyInventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
-
Patent number: 5883073Abstract: The invention is directed to a glycosylated or nonglycosylated protein which is composed of the amino acid sequence of a first .alpha. subunit common to the glycoprotein hormones linked covalently, optionally through a linker moiety, to the amino acid sequence of a second .alpha. subunit of said hormones, wherein said first and second .alpha. subunits consist of the native amino acid sequences or variants of said amino acid sequences. These proteins are useful as agonists or antagonists of glycoprotein hormone activity.Type: GrantFiled: April 3, 1997Date of Patent: March 16, 1999Assignee: Washington UniversityInventors: Irving Boime, David Ben-Menahem
-
Patent number: 5874529Abstract: Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N.sup..alpha. (.omega.-functionalized)amino acids constructed to include a spacer and a terminal functional group. One or more of these N.sup..alpha. (.omega.-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.Type: GrantFiled: December 5, 1996Date of Patent: February 23, 1999Assignees: Peptor Ltd., Yissum Research Development Company of the Hebrew UniversityInventors: Chaim Gilon, Doron Eren, Irina Zeltser, Alon Seri-Levy, Gal Bitan, Dan Muller
-
Patent number: 5874243Abstract: OLRCC15 receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing OLRCC15 receptor polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: March 28, 1997Date of Patent: February 23, 1999Assignee: SmithKline Beecham CorporationInventors: Roberto Anibal Macina, Ganesh Madhusudan Sathe
-
Patent number: 5858717Abstract: The invention provides a human formin binding protein (FBPhu) and polynucleotides which identify and encode FBPhu. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of FBPhu.Type: GrantFiled: June 11, 1997Date of Patent: January 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal
-
Patent number: 5858686Abstract: A novel expression cloning method is provided for the detection, identification and purification of target proteins capable of binding at least to a tryosine-phosphorylated domain of a eukaryotic tyrosine kinase using novel peptide probes comprising an amino acid sequence substantially corresponding to a portion of a tyrosine-phosphorylated domain of a tyrosine kinase. The probe has at least one phosphorlated tyrosine residue and may be detectably labeled. Also disclosed is a method for preparing the probe, a method for mapping to a chormosome a gene encoding a protein capable of binding to tyrosine-phosphorylated domains of tyrosine kinases, and a method for purifiying such a protein with the probe. Non-limiting examples of novel proteins discovered using the above cloning method include GRB-1, GRB-2, GRB-3, GRB-4 and GRB-7, as well as nucleic acid encoding these proteins, and methods for detecting these proteins are also provided.Type: GrantFiled: October 4, 1995Date of Patent: January 12, 1999Assignee: New York UniversityInventors: Joseph Schlessinger, Edward Y. Skolnik, Benjamin L. Margolis
-
Patent number: 5858793Abstract: Methods of maintaining or providing sterile or specific pathogen free environments are disclosed. The methods involve the use of semi-permeable membrane materials between the sterile or pathogen free environment and surrounding potentially hostile environments.Type: GrantFiled: October 30, 1996Date of Patent: January 12, 1999Assignee: Hampshire Advisory and Technical Services LimitedInventors: Michael Wilson, Philip Monro
-
Patent number: 5854081Abstract: Stable over-expression of native and hexahistidine/FLAG extended recombinant human adenosine receptors permits recovery of membranes and membrane fragments bearing a high density of adenosine receptors. Cell lines expressing all four sub-types of human adenosine receptors have been identified. The receptors, and membranes and membrane fragments bearing the same, can be used in assays to screen compounds for binding ability to the adenosine receptors, such as potential pharmaceutical agents.Type: GrantFiled: June 20, 1996Date of Patent: December 29, 1998Assignee: The University of Patent FoundationInventors: Joel Linden, Heidi Taylor, Anna Robeva, Robin Woodard, Xiaowei Jin
-
Patent number: 5849515Abstract: A selective culture medium which permits simultaneous detection of total coliform and Escherichia coli in a test sample with a single growth phase incubation period. The culture medium includes the required components of: (i) carbon nutrients, (ii) a nitrogen nutrient, (iii) a source of metabolizable potassium, (iv) a source of metabolizable phosphate, (v) vitamins, (vi) minerals, (vii) amino acids, (viii) sodium pyruvate, (ix) a bactericidal system selective for non-coliform bacteria which includes methylene blue, erythromycin and an azide, and (x) a sensible indicator selectively metabolized by Escherichia coli to the exclusion of other coliforms.Type: GrantFiled: January 30, 1997Date of Patent: December 15, 1998Assignee: Hach CompanyInventor: Michael A. Grant
-
Patent number: 5846940Abstract: A corneal therapeutic agent comprises at least one of a hexapeptide and a pharmacologically acceptable salt thereof, represented by formula (I) shown below, and a pharmacologically acceptable carrier,A-B-Pro-C-D-E (I)where A is L- or D-arginine or lysine whose N-terminal amino group is deaminated, alkylated or acylated; B is L- or D-arginine, lysine or hystidine; Pro is L- or D-proline; C is L- or D-tyrosine, tryptophane, or phenylalanine; D is L- or D-valine, isoleucine, or leucine having an amino group whose hydrogen atom may be substituted with an alkyl group having 1 to 4 carbon atoms; E is L- or D-valine, isoleucine or leucine having a C-terminal carboxylic group which is unsubstituted or substituted with --COOR, --CH.sub.2 OR or --CONHR, where R represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.Type: GrantFiled: February 3, 1997Date of Patent: December 8, 1998Assignee: Sinseiro OkamotoInventors: Sinseiro Okamoto, Sakae Amagaya, Kenji Sakamoto, Masanao Kanitani